1.1. Background: Renal Cell Carcinoma (RCC) accounts for approximately 3% of all malignant diseases. As the population in the Western world grows older more patients are treated with Dual Antiplatelet Therapy (DAPT) for cardio-vascular diseases. We sought to understand the morbidity associated with open surgical for presumably malignant renal masses in patients undergoing open renal surgery.
